Dermatologic examinations can reveal manifestations of diabetes, dyslipidemia, and heart disease, providing the clinician an opportunity to work with the patient and his or her primary care provider. Additionally, there is an established clinical link between psoriasis and an increased risk for insulin resistance, obesity, dyslipidemia, and hypertension.

Also available is “Reducing risks: Anti-inflammatory therapy is panacea for psoriasis, comorbidities” covering the potential effect psoriasis therapy may have on the likelihood of developing cardiometabolic disorders and on the cutaneous manifestations of diabetes, cardiovascular disease, and dyslipidemia. Also coming is an audio interview featuring ideas on how to use office visit time to quickly check for signs of cardiometabolic disorders and how, in general, dermatologists can be more alert to the problem and take a more active role.

For an overview of cardiometabolic disorders plus a complete list of related articles in the series, read “Cardiometabolic Disorders & Weight: Action for Outcomes.”

SERIES CONTENT

All systems go: Association between psoriasis, metabolic syndrome is strong
The evidence linking psoriasis to metabolic syndrome and cardiovascular disease is overwhelming, classifying psoriasis as a systemic disease and not simply a disease of the skin.

Reducing risks: Anti-inflammatory therapy is panacea for psoriasis, comorbidities
Psoriatics are at an increased risk for developing several comorbidities, including diabetes, obesity, dyslipidemia and hypertension—all of which are components of metabolic syndrome.